Logo image of PRE

PRENETICS GLOBAL LTD-CL A (PRE) Stock Fundamental Analysis

USA - NASDAQ:PRE - KYG722451229 - Common Stock

14.81 USD
+0.43 (+2.99%)
Last: 10/8/2025, 8:09:09 PM
14.94 USD
+0.13 (+0.88%)
After Hours: 10/8/2025, 8:09:09 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRE. PRE was compared to 101 industry peers in the Health Care Providers & Services industry. PRE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, PRE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PRE has reported negative net income.
In the past 5 years PRE always reported negative net income.
In the past 5 years PRE reported 4 times negative operating cash flow.
PRE Yearly Net Income VS EBIT VS OCF VS FCFPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.50%, PRE is doing worse than 84.16% of the companies in the same industry.
PRE has a Return On Equity of -31.41%. This is in the lower half of the industry: PRE underperforms 69.31% of its industry peers.
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
PRE Yearly ROA, ROE, ROICPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

PRE's Gross Margin of 42.48% is fine compared to the rest of the industry. PRE outperforms 70.30% of its industry peers.
PRE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for PRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
PRE Yearly Profit, Operating, Gross MarginsPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

6

2. Health

2.1 Basic Checks

PRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRE has more shares outstanding
Compared to 1 year ago, PRE has an improved debt to assets ratio.
PRE Yearly Shares OutstandingPRE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
PRE Yearly Total Debt VS Total AssetsPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 3.31 indicates that PRE is not in any danger for bankruptcy at the moment.
PRE's Altman-Z score of 3.31 is fine compared to the rest of the industry. PRE outperforms 66.34% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that PRE is not too dependend on debt financing.
PRE has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. PRE outperforms 86.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.31
ROIC/WACCN/A
WACC8.37%
PRE Yearly LT Debt VS Equity VS FCFPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.37 indicates that PRE has no problem at all paying its short term obligations.
PRE's Current ratio of 2.37 is amongst the best of the industry. PRE outperforms 80.20% of its industry peers.
PRE has a Quick Ratio of 2.29. This indicates that PRE is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.29, PRE is doing good in the industry, outperforming 79.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.29
PRE Yearly Current Assets VS Current LiabilitesPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.17% over the past year.
The Revenue for PRE has decreased by -92.12% in the past year. This is quite bad
PRE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.65% yearly.
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%443.28%

3.2 Future

PRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.61% yearly.
The Revenue is expected to grow by 34.15% on average over the next years. This is a very strong growth
EPS Next Y20.64%
EPS Next 2Y17.66%
EPS Next 3Y25.69%
EPS Next 5Y22.61%
Revenue Next Year-56.61%
Revenue Next 2Y10.48%
Revenue Next 3Y35.45%
Revenue Next 5Y34.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PRE Yearly Revenue VS EstimatesPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
PRE Yearly EPS VS EstimatesPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRE Price Earnings VS Forward Price EarningsPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRE Per share dataPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PRE's earnings are expected to grow with 25.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.66%
EPS Next 3Y25.69%

More info and screens

0

5. Dividend

5.1 Amount

PRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRENETICS GLOBAL LTD-CL A

NASDAQ:PRE (10/8/2025, 8:09:09 PM)

After market: 14.94 +0.13 (+0.88%)

14.81

+0.43 (+2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)09-12 2025-09-12/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners10.13%
Inst Owner Change0%
Ins Owners14.52%
Ins Owner Change0%
Market Cap192.97M
Analysts80
Price Target26.52 (79.07%)
Short Float %0.44%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.43%
Min EPS beat(2)-107.26%
Max EPS beat(2)90.4%
EPS beat(4)1
Avg EPS beat(4)-32.6%
Min EPS beat(4)-107.26%
Max EPS beat(4)90.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-71.46%
Min Revenue beat(2)-73.45%
Max Revenue beat(2)-69.46%
Revenue beat(4)0
Avg Revenue beat(4)-62.2%
Min Revenue beat(4)-78.3%
Max Revenue beat(4)-27.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)85.71%
PT rev (3m)85.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.73
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-4.68
EYN/A
EPS(NY)-2.59
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.59
BVpS15.84
TBVpS12.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.48%
FCFM N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.29
Altman-Z 3.31
F-ScoreN/A
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y20.64%
EPS Next 2Y17.66%
EPS Next 3Y25.69%
EPS Next 5Y22.61%
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%443.28%
Revenue Next Year-56.61%
Revenue Next 2Y10.48%
Revenue Next 3Y35.45%
Revenue Next 5Y34.15%
EBIT growth 1Y-19586.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A